Scandinavian Biopharma recruits Anna Hill as Clinical Operations Manager

Scandinavian Biopharma is now strengthening its organization by recruiting Anna Hill to the new position as Clinical Operations Manager. The company is in late clinical development phase with several ongoing clinical studies for the ETEC vaccine candidate ETVAX®. Anna will have the overall responsibility for the company's clinical development program and be responsible for ensuring that ongoing and future clinical trials are performed in a compliant and efficient manner. Anna has solid experience from similar positions at pharmaceutical companies such as Moberg Pharma and Amgen.

- To be able to implement our ambitious clinical development program we needs to strengthen the organisation within Clinical Operations. Anna's experience and skills will be very important for us and I am very pleased to welcome her to Scandinavian Biopharma, says Björn Sjöstrand, CEO of Scandinavian Biopharma.

- I am very excited to contribute in developing the clinical trial business of an innovative and expanding company like Scandinavian Biopharma. I really look forward to be a part in the development of a vaccine that significantly can have an impact on the global health. In this position I can combine my past experiences with the strong driving force that exists at Scandinavian Biopharma”, says Anna Hill.

Initially, Anna's focus will be on ETVAX® clinical trial programs in Africa. In 2019, a phase I study was started in Zambia aiming to establish the optimal dose of ETVAX® for children and to investigate the benefits of a booster dose. The Zambia study will be followed by a Phase IIb study in Gambia with the aim of establishing the safety, immune response and protective effect of ETVAX®.

Ämnen

Kategorier

Scandinavian Biopharma

We are a research-based specialty biopharma company determined to give people worldwide a longer and better life.

We are developing the first vaccine for protection against diarrhoea caused by ETEC in both travellers and endemic populations.

We distribute a wide range of specialty biopharma products with focus on vaccines and immunoglobulins.

www.scandinavianbiopharma.se

Scandinavian Biopharma rekryterar Anna Hill som Clinical Operations Manager

Scandinavian Biopharma förstärker nu sin organisation genom att rekrytera Anna Hill till den nya positionen Clinical Operations Manager. Anna kommer ha det övergripande ansvaret för företagets kliniska utvecklingsprogram och ansvara för att säkerställa att pågående och framtida kliniska prövningar utförs högkvalitativt och effektivt.

Scandinavian Biopharma secures €10.6 million from EDCTP for a Phase III trial of ETVAX® in children in low- and middle-income countries

Scandinavian Biopharma has been awarded a €10.6 million grant from EDCTP for a Phase III clinical trial of the ETEC vaccine candidate ETVAX®. The project will include the development and manufacturing of an all-in-one vaccine formulation that will be tailor-made for the paediatric population in LMIC. The main purpose is to make the vaccine preparation more fieldable and user-friendly.

We have successfully completed the enrolment of the first cohort including 40 adults in our study in Zambia

We are proud to announce that the first cohort of 40 adults was enrolled in our Phase I study in Zambia. The study is part of a late phase development program in Africa funded by EDCTP with 7,4 million Euro. The program consists of two clinical trials and is initiated with a Phase I trial in Zambia to evaluate the optimal dose of ETVAX® and the benefits of a booster dose in young children.

Scandinavian Biopharma officially starts their late phase development program in Africa funded by EDCTP

This trial will establish the exact safe and immunogenic dose of the vaccine in young children (6-23 months of age) as well as to explore the potential benefits of a third booster dose. The study will be initiated in healthy adults and followed by young children (6-23 months of age) in Zambia starting from May 2019.

Scandinavian Biopharma’s expansion requires expanded premises

We are expanding the business so much that we need larger premises. During the pandemic, the company has hired many new employees in research, clinical development, registration, manufacturing and sales. The space is specially adapted for Scandinavian Biopharma's operations and has a tailor-made, state of the art laboratory with a process development unit as well as a modern meeting place.

Vi är ett forskningsbaserat biotechföretag fast beslutna att ge människor i hela världen ett längre och bättre liv.

Vi utvecklar det första vaccinet i världen mot diarré orsakad av ETEC för att skydda både barn och vuxna i endemiska länder och resenärer till högriskdestinationer.

Vi distribuerar ett brett sortiment av biologiska specialistläkemedel med fokus på vacciner och immunglobuliner.